Items where authors include "Billingham, L."

Article

Stevens, A. orcid.org/0000-0002-4878-3871, Schreeche-Powell, E., Billingham, L. et al. (1 more author) (2025) Interventionitis in the criminal justice system: three English cases. Critical Criminology. ISSN 1205-8629

Goodyear, C.S., Patel, A., Barnes, E. et al. (118 more authors) (2024) Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. The Lancet Rheumatology, 6 (6). e339-e351. ISSN 2665-9913

Goodyear, C.S., Patel, A., Barnes, E. et al. (119 more authors) (2024) Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. The Lancet Rheumatology, 6 (6). e339-e351. ISSN 2665-9913

Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407

Woll, P.J. orcid.org/0000-0002-1118-0831, Gaunt, P., Gaskell, C. et al. (12 more authors) (2023) Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata. British Journal of Cancer, 129 (9). pp. 1490-1499. ISSN 0007-0920

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine. ISSN 1078-8956

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine, 29 (7). pp. 1760-1774. ISSN 1078-8956

Woll, P., Gaunt, P., Danson, S. et al. (8 more authors) (2022) Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP) : a randomised, double-blind, placebo-controlled phase II trial. Lung Cancer, 171. pp. 26-33. ISSN 0169-5002

Blagden, S.P., Billingham, L., Brown, L.C. et al. (13 more authors) (2020) Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement. British Journal of Cancer, 122 (4). pp. 473-482. ISSN 0007-0920

Forker, L., Gaunt, P., Sioletic, S. et al. (13 more authors) (2018) The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma. British Journal of Cancer, 118 (5). pp. 698-704. ISSN 0007-0920

Ferry, D., Billingham, L., Jarrett, H. et al. (16 more authors) (2017) Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer, 83. pp. 302-312. ISSN 0959-8049

James, N., Pirrie, S., Pope, A. et al. (17 more authors) (2016) TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment, 20. 53. ISSN 1366-5278

Conference or Workshop Item

Kirton, L., Apps, J., Lawson, A. et al. (16 more authors) (2024) CTNI-16. Monogerm, a novel proof-of-principle Bayesian phase II trial design of carboplatin or vinblastine monotherapy induction prior to radiotherapy for intracranial germinoma. In: 2024 Society for Neuro-Oncology’s 29th Annual Meeting and Education Day, 21-24 Nov 2024, Houston, Texas.